6 Result(s)
within
Darran P. O’Connor
Oncology
-
Article
Open AccessComplexation of histone deacetylase inhibitor belinostat to Cu(II) prevents premature metabolic inactivation in vitro and demonstrates potent anti-cancer activity in vitro and ex vivo in colon cancer
The histone deacetylase inhibitor (HDACi), belinostat, has had limited therapeutic impact in solid tumors, such as colon cancer, due to its poor metabolic stability. Here we evaluated a novel belinostat prodru...
-
Article
Open AccessA novel mechanism of regulation of the anti-metastatic miR-31 by EMSY in breast cancer
miR-31 is well known as an anti-metastatic microRNA (miRNA) in the context of breast cancer. However, to date the mechanism of regulation of this miRNA has yet to be elucidated. The recent publication by Viré et ...
-
Article
Open AccessPeroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer
Peroxiredoxin-1 (PRDX1) is a multifunctional protein, acting as a hydrogen peroxide (H2O2) scavenger, molecular chaperone and immune modulator. Although differential PRDX1 expression has been described in many tu...
-
Article
Open AccessTumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen
We previously reported an association between tumor-specific 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-CoAR) expression and a good prognosis in breast cancer. Here, the predictive value of HMG-CoAR...
-
Article
Open AccessValidation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer
Conflicting data exist regarding the prognostic and predictive impact of survivin (BIRC5) in breast cancer. We previously reported survivin cytoplasmic-to-nuclear ratio (CNR) as an independent prognostic indic...
-
Article
Open AccessTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer
Our group previously reported that tumour-specific expression of the rate-limiting enzyme in the mevalonate pathway, 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-CoAR) is associated with more favourab...
